Cidara TherapeuticsCDTX
CDTX
About: Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Employees: 73
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
416% more capital invested
Capital invested by funds: $35.6M [Q3] → $184M (+$148M) [Q4]
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
325% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 4
200% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 3 (+2) [Q4]
50.5% more ownership
Funds ownership: 46.99% [Q3] → 97.5% (+50.5%) [Q4]
48% more funds holding
Funds holding: 27 [Q3] → 40 (+13) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$35
60%
upside
Avg. target
$39
77%
upside
High target
$46
110%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Needham Joseph Stringer 22% 1-year accuracy 26 / 118 met price target | 60%upside $35 | Buy Reiterated | 10 Apr 2025 |
Citizens Capital Markets Roy Buchanan 13% 1-year accuracy 3 / 24 met price target | 110%upside $46 | Market Outperform Initiated | 12 Mar 2025 |
HC Wainwright & Co. Ed Arce 33% 1-year accuracy 50 / 152 met price target | 60%upside $35 | Buy Maintained | 10 Mar 2025 |
Financial journalist opinion
Based on 3 articles about CDTX published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors.
Neutral
GlobeNewsWire
3 weeks ago
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted Timothy Alefantis, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 27,000 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of March 31, 2025. The stock option has an exercise price of $21.54 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder.
Neutral
GlobeNewsWire
3 weeks ago
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that company management will participate in the 24th Annual Needham Virtual Healthcare Conference. Details are as follows: Event: 24th Annual Needham Virtual Healthcare Conference Date: Wednesday, April 9, 2025 Time: 11:00 AM ET Format: Presentation Webcast: https://wsw.com/webcast/needham146/cdtx/2261559 A replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know
The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 month ago
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the “Other pharmaceuticals as preventive tools” panel at a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The meeting, titled “What research is important to prepare and respond to H5N1 influenza outbreaks,” will be held virtually on March 19, 2025, from 1:00-7:15pm Central European Time (CET)/5:00-11:15am Pacific Time (PT), and the panel discussion will take place from 6:30-7:00 pm CET/10:30-11:00am PT.
Neutral
GlobeNewsWire
1 month ago
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025
SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada.
Neutral
GlobeNewsWire
1 month ago
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology
Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status
Neutral
GlobeNewsWire
1 month ago
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates.
Neutral
GlobeNewsWire
2 months ago
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer
Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning companies from R&D to commercialization Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning companies from R&D to commercialization
Positive
Seeking Alpha
2 months ago
Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention
Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388's safety and efficacy. CD388 inhibits viral replication and activates the immune response, and its mechanism of action actually received the FDA's Fast Track designation.
Charts implemented using Lightweight Charts™